Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Earnings of -$1.82 Per Share
Brokerages expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post earnings per share (EPS) of ($1.82) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.95) and the highest is ($1.67). Alnylam Pharmaceuticals reported earnings per share of ($1.06) in the same quarter last year, which indicates a negative year-over-year growth rate of 71.7%. The company is expected to issue its next earnings report on Tuesday, November 6th.
On average, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($6.65) per share for the current fiscal year, with EPS estimates ranging from ($6.96) to ($6.23). For the next fiscal year, analysts forecast that the firm will report earnings of ($7.02) per share, with EPS estimates ranging from ($8.74) to ($5.88). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.11. The company had revenue of $29.91 million for the quarter, compared to analysts’ expectations of $16.96 million. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. Alnylam Pharmaceuticals’s quarterly revenue was up 87.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.07) EPS.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the transaction, the chief operating officer now directly owns 1,916 shares of the company’s stock, valued at approximately $229,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John Maraganore sold 50,000 shares of the stock in a transaction dated Wednesday, July 25th. The shares were sold at an average price of $105.39, for a total transaction of $5,269,500.00. Following the completion of the transaction, the chief executive officer now directly owns 201,297 shares in the company, valued at $21,214,690.83. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,063 shares of company stock worth $5,733,678. Insiders own 4.30% of the company’s stock.
Large investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. grew its position in shares of Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 268,111 shares of the biopharmaceutical company’s stock worth $26,406,000 after purchasing an additional 20,357 shares in the last quarter. Amalgamated Bank grew its position in shares of Alnylam Pharmaceuticals by 11.3% during the 2nd quarter. Amalgamated Bank now owns 20,420 shares of the biopharmaceutical company’s stock worth $2,011,000 after purchasing an additional 2,080 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 5.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 277,352 shares of the biopharmaceutical company’s stock worth $33,033,000 after purchasing an additional 14,936 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 410.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 7,650 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 6,150 shares in the last quarter. Finally, Riverhead Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 195.6% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares in the last quarter. Hedge funds and other institutional investors own 93.36% of the company’s stock.
Shares of ALNY stock traded up $2.18 on Thursday, reaching $97.14. The stock had a trading volume of 802,411 shares, compared to its average volume of 999,319. The company has a quick ratio of 13.22, a current ratio of 13.22 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 12 month low of $74.50 and a 12 month high of $153.99.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Further Reading: Return on Investment (ROI) Defined, Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.